These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 1568412)

  • 61. Value of BCA-225 in the cytologic diagnosis of malignant effusions: an immunocytochemical study of 197 cases.
    Loy TS; Diaz-Arias AA; Bickel JT
    Mod Pathol; 1990 May; 3(3):294-7. PubMed ID: 2194212
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Tumor markers in the diagnosis of ascitic and pleural puncture fluids].
    Mezger J; Lamerz R; Arnholdt H; Huhn D; Wilmanns W
    Onkologie; 1986 Feb; 9(1):11-6. PubMed ID: 3523341
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Correlation of cytologic examination with ELISA assays for hyaluronan and soluble CD44v6 levels in evaluation of effusions.
    Afify A; Lynne LC; Howell L
    Diagn Cytopathol; 2007 Feb; 35(2):105-10. PubMed ID: 17230576
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Use of two epithelium-specific monoclonal antibodies for diagnosis of malignancy in serous effusions.
    Epenetos AA; Canti G; Taylor-Papadimitriou J; Curling M; Bodmer WF
    Lancet; 1982 Nov; 2(8306):1004-6. PubMed ID: 6127499
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Application of Leu M5 (CD 11c) antibody in the cytodiagnosis of body fluids: preliminary results.
    Berena J; Sun NC
    J Clin Lab Anal; 1993; 7(1):19-25. PubMed ID: 8093902
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Detection of carbonic anhydrase IX protein in the diagnosis of malignant pleural effusion by enzyme-linked immunosorbent assay and immunocytochemistry.
    Liao ND; Lee WY
    Cancer Cytopathol; 2012 Aug; 120(4):269-75. PubMed ID: 22367930
    [TBL] [Abstract][Full Text] [Related]  

  • 67. E-cadherin and calretinin as immunocytochemical markers to differentiate malignant from benign serous effusions.
    He DN; Zhu HS; Zhang KH; Jin WJ; Zhu WM; Li N; Li JS
    World J Gastroenterol; 2004 Aug; 10(16):2406-8. PubMed ID: 15285029
    [TBL] [Abstract][Full Text] [Related]  

  • 68. D2-40 is not a specific marker for cells of mesothelial origin in serous effusions.
    Bassarova AV; Nesland JM; Davidson B
    Am J Surg Pathol; 2006 Jul; 30(7):878-82. PubMed ID: 16819331
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Flow cytometric immunphenotyping of epithelial cancer cells in effusions--technical considerations and pitfalls.
    Dong HP; Holth A; Berner A; Davidson B; Risberg B
    Cytometry B Clin Cytom; 2007 Sep; 72(5):332-43. PubMed ID: 17226863
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry.
    Su XY; Li GD; Liu WP; Xie B; Jiang YH
    Diagn Cytopathol; 2011 Dec; 39(12):900-8. PubMed ID: 20836004
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Tumor markers in the diagnosis of malignant serous effusions.
    Cascinu S; Del Ferro E; Barbanti I; Ligi M; Fedeli A; Catalano G
    Am J Clin Oncol; 1997 Jun; 20(3):247-50. PubMed ID: 9167746
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Static DNA cytometry as a diagnostic aid in effusion cytology: II. DNA aneuploidy for identification of neoplastic cells in equivocal effusions.
    Motherby H; Nadjari B; Remmerbach T; Marcy T; Pomjanskaja N; Müller W; Knops K; Häussinger D; Strauer BE; Böcking A
    Anal Quant Cytol Histol; 1998 Jun; 20(3):162-8. PubMed ID: 9642442
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Diagnostic interest of the monoclonal antibody CA1 in malignant pleural effusion.
    Font P; Palacìn A; Font J; Faus R; Molina R; Ballesta AM; Cardesa A; Ingelmo M
    Int J Biol Markers; 1987; 2(3):157-60. PubMed ID: 2453591
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Diagnostic accuracy of the immunocytochemical study of body fluids.
    Li CY; Ziesmer SC; Wong YC; Yam LT
    Acta Cytol; 1989; 33(5):667-73. PubMed ID: 2675517
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Combined cytomorphologic and immunophenotypic approach to evaluation of effusions for lymphomatous involvement.
    Dunphy CH
    Diagn Cytopathol; 1996 Dec; 15(5):427-30. PubMed ID: 8989548
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Cytological study of serous effusions with the aid of tumour markers.
    Ray K; Mittal S; Gupta H; Jain M
    J Indian Med Assoc; 1999 Jan; 97(1):11-2, 19. PubMed ID: 10549179
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Effusion cytology of renal cell carcinoma.
    Renshaw AA; Comiter CV; Nappi D; Granter SR
    Cancer; 1998 Jun; 84(3):148-52. PubMed ID: 9678728
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Use of cholesterol and soluble tumour markers CEA and syndecan-2 in pleural effusions in cases of inconclusive cytology.
    Gulyas M; Fillinger J; Kaposi AD; Molnar M
    J Clin Pathol; 2019 Aug; 72(8):529-535. PubMed ID: 31028099
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Immunohistochemical panel for distinguishing between carcinoma and reactive mesothelial cells in serious effusions.
    Lee JS; Nam JH; Lee MC; Park CS; Juhng SW
    Acta Cytol; 1996; 40(4):631-6. PubMed ID: 8693877
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Minimally Invasive, Maximally Effective: The Power of Precision Cytoanalysis on Effusion Samples-A Comprehensive Exploration from Traditional Methods to Innovative Approaches.
    Souza da Silva R; Schmitt F
    Surg Pathol Clin; 2024 Sep; 17(3):453-481. PubMed ID: 39129143
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.